About Kardigan
Kardigan is a company based in San Francisco (United States) founded in 2023 by Tassos Gianakakos.. Kardigan has raised $554 million across 2 funding rounds from investors including Fidelity Investments, T. Rowe Price and Arch Venture Partners. Kardigan has completed 1 acquisition, including Prolaio. Kardigan offers products and services including Personalized Medicines, R&D Platform, and Cardiac Intelligence Platform. Kardigan operates in a competitive market with competitors including Suanfarma, Enzene Biosciences, Hybio Pharmaceutical, Nephron Pharmaceuticals and Quotient Sciences, among others.
- Headquarter San Francisco, United States
- Founders Tassos Gianakakos
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$554 M (USD)
in 2 rounds
-
Latest Funding Round
$254 M (USD), Series B
Oct 14, 2025
-
Investors
Fidelity Investments
& 4 more
-
Employee Count
Employee Count
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Kardigan
Kardigan offers a comprehensive portfolio of products and services, including Personalized Medicines, R&D Platform, and Cardiac Intelligence Platform. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Targets specific cardiovascular disease drivers for effective treatments.
Uses AI to optimize clinical trials and drug discovery processes.
Analyzes real-world data for safer and more efficient drug development.
Unlock access to complete
Funding Insights of Kardigan
Kardigan has successfully raised a total of $554M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $254 million completed in October 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 2
- Last Round Series B — $254.0M
-
First Round
First Round
(13 Jan 2025)
- Investors Count 5
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct, 2025 | Amount | Series B - Kardigan | Valuation |
investors |
|
| Jan, 2025 | Amount | Series A - Kardigan | Valuation | Perceptive Advisors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Kardigan
Kardigan has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include Fidelity Investments, T. Rowe Price and Arch Venture Partners. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Health-tech companies are targeted for venture capital investments.
|
Founded Year | Domain | Location | |
|
Venture capital firm focused on life science companies
|
Founded Year | Domain | Location | |
|
Investment services are offered to ambitious builders worldwide.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Kardigan
Kardigan has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Prolaio. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Company offers prescriptive analytics for pharmaceutical Industry
|
2021 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - Kardigan
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Kardigan Comparisons
Competitors of Kardigan
Kardigan operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Suanfarma, Enzene Biosciences, Hybio Pharmaceutical, Nephron Pharmaceuticals and Quotient Sciences, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Generics, nutraceuticals, and APIs are developed by Suanfarma.
|
|
| domain | founded_year | HQ Location |
Company specializing in development of Biosimilars
|
|
| domain | founded_year | HQ Location |
Polypeptide drugs and APIs are developed and manufactured.
|
|
| domain | founded_year | HQ Location |
Sterile pharmaceutical products are manufactured and contract services are provided.
|
|
| domain | founded_year | HQ Location |
APIs and finished dosage forms are developed and manufactured.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Frequently Asked Questions about Kardigan
When was Kardigan founded?
Kardigan was founded in 2023 and raised its 1st funding round 2 years after it was founded.
Where is Kardigan located?
Kardigan is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Who is the current CEO of Kardigan?
Tassos Gianakakos is the current CEO of Kardigan. They have also founded this company.
Is Kardigan a funded company?
Kardigan is a funded company, having raised a total of $554M across 2 funding rounds to date. The company's 1st funding round was a Series A of $300M, raised on Jan 13, 2025.
What does Kardigan do?
Kardigan was founded in 2023 in San Francisco, United States, as a biotechnology company. Precision medicines for cardiovascular diseases are developed, with operations centered on a late-stage portfolio. Cardiovascular drug development is modernized through personalized approaches, targeting patient-specific treatments in the biotech sector.
Who are the top competitors of Kardigan?
Kardigan's top competitors include Nephron Pharmaceuticals, Suanfarma and Enzene Biosciences.
What products or services does Kardigan offer?
Kardigan offers Personalized Medicines, R&D Platform, and Cardiac Intelligence Platform.
How many acquisitions has Kardigan made?
Kardigan has made 1 acquisition, including Prolaio.
Who are Kardigan's investors?
Kardigan has 5 investors. Key investors include Fidelity Investments, T. Rowe Price, Arch Venture Partners, Perceptive Advisors, and Sequoia Heritage.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.